ArticleJournal of experimental & clinical cancer research : CR2017

Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.

Makoto Isono et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.